Company Overview and News

 
Stock With Momentum: PBA Holdings

2018-10-05 theedgemarkets
PBA Holdings Bhd (-ve) TRADING of shares in PBA Holdings Bhd (fundamental: 1.8/3, valuation: 2/3) triggered our momentum algorithm yesterday for the fifth time this year. PBA closed up two sen or 1.57% at RM1.29 with a market capitalisation of RM426.99 million, after 956,300 shares were traded, versus the counter’s 200-day average volume of 79,794.5 shares.
5041

 
Renewed buying interest emerged in PBA, says AllianceDBS Research

2018-10-04 theedgemarkets
KUALA LUMPUR (Oct 5): AllianceDBS Research said PBA Holdings Bhd (PBA) had on Oct 4 traded higher to RM1.30 before settling at RM1.29 (up 2 sen or 1.57%).
5041

 
Vizione active, up 7.14% on bagging RM89.9m submarine pipelines job

2018-09-19 theedgemarkets
KUALA LUMPUR (Sept 19): Vizione Holdings Bhd rose 7.14% in active trade early today after it bagged an RM89.9 million contract from PBA Holdings Bhd to build submarine pipelines from Butterworth to the Macallum area on Penang Island.
5041

 
Vizione unit wins RM90mil contract

2018-09-19 thestar.com.my
In a statement yesterday, the group said it received the award letter from PBAPP, a unit of PBA Holdings Bhd, to undertake the job, known as package three-twin DN 1200mm submarine pipeline.
5041

 
FGV, MSM, Ideal Jacobs, BFood, Vizione, WCT, Damansara Realty, YFG, TM, Superlon, MMAG and PanPages

2018-09-18 theedgemarkets
KUALA LUMPUR: Based on corporate announcements and news flow today, companies that may be in focus on Wednesday (Sept 19) may include the following: FGV Holdings Bhd, MSM Malaysia Holdings Bhd, Ideal Jacobs (M) Corp Bhd, Berjaya Food Bhd, Vizione Holdings Bhd, WCT Bhd, Damansara Realty Bhd, YFG Bhd, Telekom Malaysia Bhd, Superlon Holdings Bhd, MMAG Holdings Bhd and PanPages Bhd.
4863 7235 9679 5196 MYTEF 5041 5202 0162 BSMAF 7099 1818 3484

 
Vizione bags RM90m job to build submarine pipelines in Penang

2018-09-18 theedgemarkets
KUALA LUMPUR (Sept 18): Vizione Holdings Bhd has bagged a RM89.9 million contract from PBA Holdings Bhd to build submarine pipelines from Butterworth to the Macallum area on Penang Island.
5041 BSMAF 1818

 
Stock With Momentum: PBA Holdings

2018-09-12 theedgemarkets
Trading of shares in PBA Holdings Bhd (fundamental: 2/3, valuation: 1.8/3) triggered our stocks with momentum algorithm last Friday for the second time this month.
5041

 
Study: Political appointments at state GLCs, patronage continue under Pakatan

2018-09-01 malaymail
KUALA LUMPUR, Sept 2 — Political patronage at state government-linked companies (GLC) practised by Barisan Nasional (BN) has continued in states controlled by the now-defunct Pakatan Rakyat and that of its former component member PAS, a recently released research showed.
5041

 
GUH to enjoy fruits of pricey venture soon

2018-08-03 theedgemarkets
BACK in 2013, GUH Holdings Bhd had a happy problem. It was sitting on a big cash pile and needed to figure out what to do with it.
3247 5041

 
Penang water firm’s post-tax profit down 45pc

2018-06-28 malaymail
GEORGE TOWN, June 28 — PBA Holdings Bhd (PBAHB) recorded a profit after tax (PAT) of RM37.3 million in 2017, 45 per cent lower than the preceding year.
5041

 
Penang moots regional raw water management network

2018-06-28 malaymail
GEORGE TOWN, June 28 ― The Penang state government and Penang Water Supply Corporation (PBAPP) has proposed for raw water resource management programme encompassing the northern states of the peninsula.
5041

 
Stock With Momentum: PBA Holdings

2018-06-13 theedgemarkets
SHARES in Penang water operator PBA Holdings Bhd (fundamental: 1.8/3, valuation: 2/3) triggered our momentum algorithm yesterday for the second time this year.
5041

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...